>Marché des médicaments contre les troubles obsessionnels compulsifs (TOC) au Moyen-Orient et en Afrique , par gravité (légère à modérée, modérée à sévère), par sous-type (obsessions de contamination avec compulsion de lavage/nettoyage, obsessions de préjudice avec compulsions de vérification, obsessions sans compulsions visibles, obsessions de symétrie avec compulsions de commande, d'organisation et de comptage, thésaurisation, autres), par médicaments (antidépresseurs, antipsychotiques, inhibiteurs NMDA, autres), par voie d'administration (orale, parentérale), par type de population (pédiatrie, adultes), par utilisateur final (hôpitaux, cliniques spécialisées, soins à domicile , autres), par canal de distribution (pharmacie hospitalière, pharmacie de détail, pharmacie en ligne, autres), par pays (Afrique du Sud, Arabie saoudite, Émirats arabes unis, Égypte, Koweït, Israël, reste du Moyen-Orient et de l'Afrique).
Analyse et perspectives du marché : Marché des médicaments contre les troubles obsessionnels compulsifs (TOC) au Moyen-Orient et en Afrique
Le marché des médicaments contre les troubles obsessionnels compulsifs (TOC) au Moyen-Orient et en Afrique devrait connaître une croissance du marché au cours de la période de prévision de 2021 à 2028. Data Bridge Market Research analyse que le marché croît avec un TCAC de 8,1% au cours de la période de prévision de 2021 à 2028 et devrait atteindre 26,69 millions USD d'ici 2028. L'augmentation du soutien gouvernemental aux soins de santé et la sensibilisation croissante aux produits médicamenteux TOC actuels et nouveaux sont les principaux moteurs qui ont propulsé la demande du marché au cours de la période de prévision.
Le trouble obsessionnel compulsif (TOC) fait référence à un trouble anxieux caractérisé par des pensées et des peurs déraisonnables et incontrôlables qui conduisent un individu à adopter des comportements répétitifs. Le trouble obsessionnel compulsif est un trouble connu pour obliger une personne à rester bloquée sur une pensée ou une peur particulière. Les développements dans le traitement , les thérapies et les nouveaux traitements, ainsi que les progrès dans les médicaments anxiolytiques, antipsychotiques et antidépresseurs devraient offrir diverses autres opportunités sur le marché des médicaments contre le TOC. Cependant, l'expiration des brevets des médicaments brevetés et l'introduction de la version générique des médicaments de marque sont des facteurs qui devraient freiner la croissance du marché au cours de la période de prévision.
Le rapport sur le marché des médicaments contre le TOC fournit des détails sur la part de marché, les nouveaux développements et l'analyse du pipeline de produits, l'impact des acteurs du marché national et local, analyse les opportunités en termes de poches de revenus émergentes, les changements dans la réglementation du marché, les approbations de produits, les décisions stratégiques, les lancements de produits, les expansions géographiques et les innovations technologiques sur le marché. Pour comprendre l'analyse et le scénario du marché, contactez-nous pour un briefing d'analyste, notre équipe vous aidera à créer une solution d'impact sur les revenus pour atteindre votre objectif souhaité.
Portée et taille du marché des médicaments contre les troubles obsessionnels compulsifs (TOC) au Moyen-Orient et en Afrique
Le marché des médicaments contre les troubles obsessionnels compulsifs (TOC) est segmenté en fonction de la gravité, des sous-types, des médicaments, de la voie d'administration, de la population, de l'utilisateur final et du canal de distribution. La croissance entre les segments vous aide à analyser les niches de croissance et les stratégies pour aborder le marché et déterminer vos principaux domaines d'application et la différence entre vos marchés cibles.
- En fonction de la gravité, le marché des médicaments contre les troubles obsessionnels compulsifs (TOC) au Moyen-Orient et en Afrique est segmenté en léger à modéré et modéré à sévère. En 2021, le segment modéré à sévère domine le marché des médicaments contre les troubles obsessionnels compulsifs (TOC) au Moyen-Orient et en Afrique en raison d'une augmentation du taux de prévalence des maladies infectieuses dans la population mondiale.
- Français Sur la base du sous-type, le marché des médicaments contre les troubles obsessionnels compulsifs (TOC) au Moyen-Orient et en Afrique est segmenté en obsessions de contamination avec compulsion de lavage/nettoyage, obsessions de préjudice avec compulsions de vérification, obsessions sans compulsions visibles, obsessions de symétrie avec compulsions de classement, d'organisation et de comptage, thésaurisation et autres. En 2021, les obsessions de contamination avec compulsion de lavage/nettoyage dominent le marché des médicaments contre les troubles obsessionnels compulsifs au Moyen-Orient et en Afrique en raison des développements dans le traitement, les thérapies et l'introduction de nouveaux traitements devraient dominer le marché.
- Français Sur la base des médicaments, le marché des médicaments contre les troubles obsessionnels compulsifs (TOC) au Moyen-Orient et en Afrique est segmenté en antidépresseurs, antipsychotiques, bloqueurs NMDA et autres. Les antidépresseurs sont en outre segmentés en inhibiteurs sélectifs de la recapture de la sérotonine (ISRS), inhibiteurs de la recapture de la sérotonine et de la noradrénaline (IRSN), antidépresseurs tricycliques (TCAS) et autres. Les ISRS sont en outre segmentés en fluvoxamine, fluoxétine, paroxétine, sertraline et autres. Les IRSN sont en outre segmentés en duloxétine, venlafaxine et autres. Les TCAS sont en outre segmentés en clomipramine, amitriptyline, imipramine et autres. Les antipsychotiques sont en outre segmentés en rispéridone, halopéridol, quétiapine, olanzapine, aripiprazole et autres. Les bloqueurs NMDA sont en outre segmentés en kétamine, mémantine et autres. En 2021, le segment des antidépresseurs domine le marché des médicaments contre les troubles obsessionnels compulsifs au Moyen-Orient et en Afrique en raison des progrès réalisés dans les médicaments anxiolytiques, antipsychotiques et antidépresseurs, et les solides pipelines pour le développement de nouveaux traitements devraient dominer le marché.
- On the basis of route of administration, the Middle East and Africa obsessive compulsive disorder (OCD) drugs market is segmented into oral and parenteral. Oral is further segmented into tablets, capsules, and solution. In 2021, the oral segment is dominating the Middle East and Africa obsessive obsessive-compulsive disorder (OCD) drugs market due to novel treatment, and advancements in therapies are predicted to dominate the market.
- On the basis of population, the Middle East and Africa obsessive compulsive disorder (OCD) drugs market is segmented into pediatrics and adults. In 2021, the adults segment is dominating the Middle East and Africa obsessive obsessive-compulsive disorder drug market due to research and development to enhance bioavailability, pharmacology, safety, and dosage parameters is are predicted to dominate the market.
- On the basis of end user, the Middle East and Africa obsessive compulsive disorder (OCD) drugs market is segmented into hospitals, specialty clinics, home healthcare and others. In 2021, the hospitals segment is dominating the Middle East and Africa obsessive obsessive-compulsive disorder drug market due to an increase in the cases of prevalence rate of infectious diseases among the population across the globe is predicted to dominate the market.
- On the basis of distribution channel, the Middle East and Africa obsessive compulsive disorder (OCD) drugs market is segmented into hospital pharmacy, retail pharmacy, online pharmacy and others. In 2021, hospital pharmacy segment is dominating the Middle East and Africa obsessive compulsive disorder drug market due to novel treatment and advancements in the anti-anxiety, antipsychotic and antidepressant drugs are predicted to dominate the market.
- In Middle East and Africa, South Africa is the dominant region due to rising demand for effective therapies and rising awareness about the syndrome.
Obsessive-Compulsive Disorder (OCD) Drugs Market Country Level Analysis
The OCD drugs market is analyzed, and market size information is provided on the basis of severity, subtypes, drugs, route of administration, population, end user, and distribution channel.
The countries covered in the OCD market report are the Saudi Arabia, South Africa, UAE, Israel, Kuwait, Egypt, Rest of Middle East & Africa.
Antidepressants segment.in Middle East & Africa region is expected to grow with the highest growth rate in the forecast period of 2021 to 2028 because of robust pipelines for development of newer treatment and the growth in awareness regarding the disorder.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of Middle East & Africa brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Strategic initiatives by market players and increasing generic approvals are boosting the market growth of OCD drugs market.
Obsessive-Compulsive Disorder (OCD) Drugs market also provides you with detailed market analysis for every country growth in OCD products industry with drugs sales, impact of advancement, technology, and changes in regulatory scenarios with their support for the OCD drugs market. The data is available for historic period 2010 to 2019.
Competitive Landscape and Laxative Market Share Analysis
OCD drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width, and breath, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to OCD drugs market.
The major companies operating in the global obsessive-compulsive disorder (OCD) drugs market are Mallinckrodt, , Zydus Pharmaceuticals, Inc. (a subsidiary of Zydus Cadila), Wockhardt, Lupin Pharmaceuticals, Inc., Amneal Pharmaceuticals LLC., Dr. Reddy’s Laboratories Ltd., Teva Pharmaceutical industries Ltd., Alvogen, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma USA (a subsidiary of Aurobindo Pharma), Par Pharmaceutical, Apotex Inc., Lannett, Abbott, Eli Lilly and Company, Viatria Inc., H. LUNDBECK A/S, GlaxoSmithKline plc., Pfizer Inc., Sebela Pharmaceuticals among others.
Many product launch and agreement are also initiated by the companies’ worldwide, which are also accelerating the OCD drugs market.
For instance,
- In June 2021, Mallinckrodt, a global biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has approved StrataGraft® (allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen – dsat) for the treatment of adults with thermal burns containing intact dermal elements for which surgical intervention is clinically indicated (deep partial-thickness burns).
- En juin 2021, Zydus Cadila, une société mondiale de soins de santé axée sur l'innovation, a annoncé aujourd'hui avoir signé un accord de licence non exclusif avec Gilead Sciences Inc. pour la fabrication et la distribution de Remdesivir, le médicament expérimental qui a reçu une autorisation d'utilisation d'urgence de la Food and Drug Administration (FDA) des États-Unis pour traiter les patients souffrant de symptômes graves du nouveau coronavirus. Zydus soutient la lutte contre le COVID-19 avec des produits thérapeutiques, des vaccins et des diagnostics.
- En août 2020, Wockhardt, le leader mondial de la pharmacie et des biotechnologies, a annoncé avoir conclu un accord avec le gouvernement britannique pour la fabrication de vaccins COVID-19. La fabrication sera réalisée chez CP Pharmaceuticals, une filiale de Wockhardt basée à Wrexham, dans le nord du Pays de Galles. Selon les termes de l'accord, la société a réservé une capacité de fabrication pour permettre la fourniture de plusieurs vaccins au gouvernement britannique dans sa lutte contre le COVID-19, notamment l'AZD1222, le vaccin co-inventé par l'Université d'Oxford et sa société dérivée, Vaccitech, et sous licence d'AstraZeneca.
La collaboration, le lancement de produits, l'expansion commerciale, les récompenses et la reconnaissance, les coentreprises et d'autres stratégies des acteurs du marché améliorent le marché de l'entreprise sur le marché des médicaments TOC, ce qui offre également l'avantage à l'organisation d'améliorer son offre de produits médicamenteux TOC.
SKU-
Accédez en ligne au rapport sur le premier cloud mondial de veille économique
- Tableau de bord d'analyse de données interactif
- Tableau de bord d'analyse d'entreprise pour les opportunités à fort potentiel de croissance
- Accès d'analyste de recherche pour la personnalisation et les requêtes
- Analyse de la concurrence avec tableau de bord interactif
- Dernières actualités, mises à jour et analyse des tendances
- Exploitez la puissance de l'analyse comparative pour un suivi complet de la concurrence
Table des matières
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 SEVERITY LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET APPLICATION COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PORTERS FIVE FORCES
4.2 PESTEL ANALYSIS
5 EPIDEMIOLOGY
6 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: REGULATIONS
6.1 THE U.S. REGULATORY FRAMEWORK FOR OCD DRUGS
6.2 EUROPE REGULATORY FRAMEWORK FOR OCD DRUGS
6.3 AUSTRALIA REGULATORY GUIDANCE ON OCD DRUGS
7 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: REIMBURSEMENT SCENARIO
8 COST ANALYSIS
9 MARKET OVERVIEW
9.1 DRIVERS
9.1.1 RISE IN CLINICAL TRIALS FOR OBSESSIVE-COMPULSIVE DISORDER (OCD)
9.1.2 INCREASING CASES OF OBSESSIVE-COMPULSIVE DISORDER (OCD) WORLDWIDE
9.1.3 INCREASING R&D INVESTMENT BY KEY MARKET PLAYERS
9.1.4 CHANGES IN LIFESTYLE AND ENVIRONMENTAL STRESS AMONG PEOPLE
9.1.5 INCREASING GENERIC APPROVALS
9.2 RESTRAINTS
9.2.1 RECALL OF DRUGS
9.2.2 ADVERSE EFFECTS OF DRUGS
9.2.3 STRINGENT GOVERNMENT REGULATIONS FOR OCD DRUGS DEVELOPMENT
9.2.4 UNAWARENESS AMONG PEOPLE OF EXISTENCE OF OCD
9.3 OPPORTUNITIES
9.3.1 TECHNOLOGICAL ADVANCEMENT FOR THE TREATMENT OF OBSESSIVE-COMPULSIVE DISORDER (OCD)
9.3.2 RISING COLLABORATIONS, AND MERGER & ACQUISITIONS AMONG THE MARKET PLAYERS
9.3.3 RISE IN QUALITY CONCERNS
9.4 CHALLENGES
9.4.1 USE OF ALTERNATIVE THERAPIES
9.4.2 LIMITATIONS OF CURRENT OCD TREATMENT
10 IMPACT OF COVID-19 ON MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET
10.1 IMPACT ON PRICE
10.2 IMPACT ON DEMAND
10.3 IMPACT ON SUPPLY CHAIN
10.4 STRATEGIC DECISIONS FOR MANUFACTURERS
10.5 CONCLUSION
11 MARKET BY DRUGS
11.1 TOTAL ADDRESSABLE MARKET
11.2 PATIENT POPULATION (2019-2028)
12 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SEVERITY
12.1 OVERVIEW
12.2 MODERATE TO SEVERE
12.3 MILD TO MODERATE
13 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SUBTYPE
13.1 OVERVIEW
13.2 CONTAMINATION OBSESSIONS WITH WASHING/CLEANING COMPULSION
13.3 HARM OBSESSIONS WITH CHECKING COMPULSIONS
13.4 OBSESSIONS WITHOUT VISIBLE COMPULSIONS
13.5 SYMMETRY OBSESSIONS WITH ORDERING, ARRANGING, AND COUNTING COMPULSIONS
13.6 HOARDING
13.7 OTHERS
14 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS
14.1 OVERVIEW
14.2 ANTIDEPRESSANTS
14.2.1 SELECTIVE SEROTONIN REUPTAKE INHIBITORS
14.2.1.1 FLUVOXAMINE
14.2.1.2 FLUOXETINE
14.2.1.3 PAROXETINE
14.2.1.4 SERTRALINE
14.2.1.5 OTHERS
14.2.2 SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS
14.2.2.1 DULOXETINE
14.2.2.2 VENLAFAXINE
14.2.2.3 OTHERS
14.2.3 TRICYCLIC ANTIDEPRESSANTS
14.2.3.1 CLOMIPRAMINE
14.2.3.2 AMITRIPTYLINE
14.2.3.3 IMIPRAMINE
14.2.3.4 OTHERS
14.3 ANTIPSYCHOTICS
14.3.1 RISPERIDONE
14.3.2 OLANZAPINE
14.3.3 ARIPIPRAZOLE
14.3.4 QUETIAPINE
14.3.5 HALOPERIDOL
14.3.6 OTHERS
14.4 NMDA BLOCKERS
14.4.1 MEMANTINE
14.4.2 KETAMINE
14.4.3 OTHERS
14.5 OTHERS
15 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION
15.1 OVERVIEW
15.2 ORAL
15.2.1 TABLET
15.2.2 CAPSULE
15.2.3 SOLUTION
15.3 PARENTERAL
16 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY POPULATION
16.1 OVERVIEW
16.2 ADULTS
16.3 PEDIATRICS
17 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY END USER
17.1 OVERVIEW
17.2 HOSPITALS
17.3 SPECIALTY CLINICS
17.4 HOME HEALTHCARE
17.5 OTHERS
18 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DISTRIBUTION CHANNEL
18.1 OVERVIEW
18.2 HOSPITAL PHARMACY
18.3 RETAIL PHARMACY
18.4 ONLINE PHARMACY
18.5 OTHERS
19 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION
19.1 MIDDLE EAST & AFRICA
19.1.1 SOUTH AFRICA
19.1.2 SAUDI ARABIA
19.1.3 UAE
19.1.4 KUWAIT
19.1.5 ISRAEL
19.1.6 EGYPT
19.1.7 REST OF MIDDLE EAST & AFRICA
20 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: COMPANY LANDSCAPE
20.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA
21 SWOT ANALYSIS
22 COMPANY PROFILE
22.1 SUN PHARMACEUTICAL INDUSTRIES LTD.
22.1.1 COMPANY SNAPSHOT
22.1.2 REVENUE ANALYSIS
22.1.3 COMPANY SHARE ANALYSIS
22.1.4 PRODUCT PORTFOLIO
22.1.5 RECENT DEVELOPMENTS
22.2 H. LUNDBECK A/S
22.2.1 COMPANY SNAPSHOT
22.2.2 REVENUE ANALYSIS
22.2.3 COMPANY SHARE ANALYSIS
22.2.4 PRODUCT PORTFOLIO
22.2.5 RECENT DEVELOPMENTS
22.3 TEVA PHARMACEUTICALS USA, INC. (A SUBSIDIARY OF TEVA PHARMACEUTICAL INDUSTRIES LTD.)
22.3.1 COMPANY SNAPSHOT
22.3.2 REVENUE ANALYSIS
22.3.3 COMPANY SHARE ANALYSIS
22.3.4 PRODUCT PORTFOLIO
22.3.5 RECENT DEVELOPMENTS
22.4 ELI LILLY AND COMPANY
22.4.1 COMPANY SNAPSHOT
22.4.2 REVENUE ANALYSIS
22.4.3 COMPANY SHARE ANALYSIS
22.4.4 PRODUCT PORTFOLIO
22.4.5 RECENT DEVELOPMENTS
22.5 APOTEX INC.
22.5.1 COMPANY SNAPSHOT
22.5.2 COMPANY SHARE ANALYSIS
22.5.3 PRODUCT PORTFOLIO
22.5.4 RECENT DEVELOPMENTS
22.6 VIATRIS INC.
22.6.1 COMPANY SNAPSHOT
22.6.2 REVENUE ANALYSIS
22.6.3 PRODUCT PORTFOLIO
22.6.4 RECENT DEVELOPMENTS
22.7 LANNETT
22.7.1 COMPANY SNAPSHOT
22.7.2 REVENUE ANALYSIS
22.7.3 PRODUCT PORTFOLIO
22.7.4 RECENT DEVELOPMENTS
22.8 GLAXOSMITHKLINE PLC
22.8.1 COMPANY SNAPSHOT
22.8.2 REVENUE ANALYSIS
22.8.3 PRODUCT PORTFOLIO
22.8.4 RECENT DEVELOPMENT
22.9 ALVOGEN
22.9.1 COMPANY SNAPSHOT
22.9.2 PRODUCT PORTFOLIO
22.9.3 RECENT DEVELOPMENTS
22.1 PFIZER INC.
22.10.1 COMPANY SNAPSHOT
22.10.2 REVENUE ANALYSIS
22.10.3 PRODUCT PORTFOLIO
22.10.4 RECENT DEVELOPMENTS
22.11 AMNEAL PHARMACEUTICALS LLC
22.11.1 COMPANY SNAPSHOT
22.11.2 REVENUE ANALYSIS
22.11.3 PRODUCT PORTFOLIO
22.11.4 RECENT DEVELOPMENTS
22.12 DR.REDDY’S LABORATORIES LTD.
22.12.1 COMPANY SNAPSHOT
22.12.2 REVENUE ANALYSIS
22.12.3 PRODUCT PORTFOLIO
22.12.4 RECENT DEVELOPMENTS
22.13 AUROBINDO PHARMA USA (A SUBSIDIARY OF AUROBINDO PHARMA)
22.13.1 COMPANY SNAPSHOT
22.13.2 REVENUE ANALYSIS
22.13.3 PRODUCT PORTFOLIO
22.13.4 RECENT DEVELOPMENTS
22.14 ABBOTT
22.14.1 COMPANY SNAPSHOT
22.14.2 REVENUE ANALYSIS
22.14.3 PRODUCT PORTFOLIO
22.14.4 RECENT DEVELOPMENTS
22.15 LUPIN PHARMACEUTICALS, INC.
22.15.1 COMPANY SNAPSHOT
22.15.2 REVENUE ANALYSIS
22.15.3 PRODUCT PORTFOLIO
22.15.4 RECENT DEVELOPMENTS
22.16 MALLINCKRODT
22.16.1 COMPANY SNAPSHOT
22.16.2 REVENUE ANALYSIS
22.16.3 PRODUCT PORTFOLIO
22.16.4 RECENT DEVELOPMENTS
22.17 PAR PHARMACEUTICAL
22.17.1 COMPANY SNAPSHOT
22.17.2 REVENUE ANALYSIS
22.17.3 PRODUCT PORTFOLIO
22.17.4 RECENT DEVELOPMENTS
22.18 SEBELA PHARMACEUTICALS
22.18.1 COMPANY SNAPSHOT
22.18.2 PRODUCT PORTFOLIO
22.18.3 RECENT DEVELOPMENT
22.19 ZYDUS PHARMACEUTICALS USA INC. (A SUBSIDIARY OF ZYDUS CADILA)
22.19.1 COMPANY SNAPSHOT
22.19.2 REVENUE ANALYSIS
22.19.3 PRODUCT PORTFOLIO
22.19.4 RECENT DEVELOPMENTS
22.2 WOCKHARDT
22.20.1 COMPANY SNAPSHOT
22.20.2 REVENUE ANALYSIS
22.20.3 PRODUCT PORTFOLIO
22.20.4 RECENT DEVELOPMENTS
23 QUESTIONNAIRE
24 RELATED REPORTS
Liste des tableaux
LIST OF TABLES
TABLE 1 BELOW MENTIONED ARE THE COST OF OCD DRUGS, AVAILABLE IN DIFFERENT DOSAGE FORMS SUCH AS A TABLET, CAPSULE, PARENTAL, AND STRENGTHS USED MIDDLE EAST AND AFRICALY TO TREAT OBSESSIVE-COMPULSIVE DISORDER.
TABLE 2 DRUGS UNDER INVESTIGATIONS FOR OCD
TABLE 3 R&D COST BY KEY MARKET PLAYERS (USD MILLIONS) (2020)
TABLE 4 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 5 MIDDLE EAST AND AFRICA MODERATE TO SEVERE IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 6 MIDDLE EAST AND AFRICA MILD TO MODERATE IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 7 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SUB TYPE 2019-2028 (USD MILLION)
TABLE 8 MIDDLE EAST AND AFRICA CONTAMINATION OBSESSIONS WITH WASHING/CLEANING COMPULSION IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 9 MIDDLE EAST AND AFRICA HARM OBSESSIONS WITH CHECKING COMPULSIONS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 10 MIDDLE EAST AND AFRICA OBSESSIONS WITHOUT VISIBLE COMPULSIONS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 11 MIDDLE EAST AND AFRICA SYMMETRY OBSESSIONS WITH ORDERING, ARRANGING, AND COUNTING COMPULSIONS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 12 MIDDLE EAST AND AFRICA HOARDING IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 13 MIDDLE EAST AND AFRICA OTHERS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 14 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 15 MIDDLE EAST AND AFRICA ANTIDEPRESSANTS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 16 MIDDLE EAST AND AFRICA ANTIDEPRESSANTS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 17 MIDDLE EAST AND AFRICA SELECTIVE SEROTONIN REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 18 MIDDLE EAST AND AFRICA SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 19 MIDDLE EAST AND AFRICA TRICYCLIC ANTIDEPRESSANTS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 20 MIDDLE EAST AND AFRICA ANTIPSYCHOTICS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 21 MIDDLE EAST AND AFRICA ANTIPSYCHOTICS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 22 MIDDLE EAST AND AFRICA NMDA BLOCKERS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 23 MIDDLE EAST AND AFRICA NMDA BLOCKERS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 24 MIDDLE EAST AND AFRICA OTHERS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 25 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 26 MIDDLE EAST AND AFRICA ORAL IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 27 MIDDLE EAST AND AFRICA ORAL IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 28 MIDDLE EAST AND AFRICA PARENTERAL IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 29 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY POPULATION, 2019-2028 (USD MILLION)
TABLE 30 MIDDLE EAST AND AFRICA ADULTS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION 2019-2028 (USD MILLION)
TABLE 31 MIDDLE EAST AND AFRICA PEDIATRICS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 32 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 33 MIDDLE EAST AND AFRICA HOSPITALS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 34 MIDDLE EAST AND AFRICA SPECIALTY CLINICS IN OBSESSIVE-COMPULSIVE (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 35 MIDDLE EAST AND AFRICA HOME HEALTHCARE IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 36 MIDDLE EAST AND AFRICA OTHERS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 37 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DISTRIBUTION CHANNEL 2019-2028 (USD MILLION)
TABLE 38 MIDDLE EAST AND AFRICA HOSPITAL PHARMACY IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 39 MIDDLE EAST AND AFRICA RETAIL PHARMACY IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 40 MIDDLE EAST AND AFRICA ONLINE PHARMACY IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 41 MIDDLE EAST AND AFRICA OTHERS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 42 MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
TABLE 43 MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 44 MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SUBTYPE, 2019-2028 (USD MILLION)
TABLE 45 MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 46 MIDDLE EAST & AFRICA ANTIDEPRESSANTS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 47 MIDDLE EAST & AFRICA SELECTIVE SEROTONIN REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 48 MIDDLE EAST & AFRICA SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 49 MIDDLE EAST & AFRICA TRICYCLIC ANTIDEPRESSANTS (TCAS) IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 50 MIDDLE EAST & AFRICA ANTIPSYCHOTICS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 51 MIDDLE EAST & AFRICA NMDA BLOCKERS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 52 MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 53 MIDDLE EAST & AFRICA ORAL IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 54 MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY POPULATION, 2019-2028 (USD MILLION)
TABLE 55 MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 56 MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 57 SOUTH AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 58 SOUTH AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SUBTYPE, 2019-2028 (USD MILLION)
TABLE 59 SOUTH AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 60 SOUTH AFRICA ANTIDEPRESSANTS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 61 SOUTH AFRICA SELECTIVE SEROTONIN REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 62 SOUTH AFRICA SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 63 SOUTH AFRICA TRICYCLIC ANTIDEPRESSANTS (TCAS) IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 64 SOUTH AFRICA ANTIPSYCHOTICS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 65 SOUTH AFRICA NMDA BLOCKERS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 66 SOUTH AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 67 SOUTH AFRICA ORAL IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 68 SOUTH AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY POPULATION, 2019-2028 (USD MILLION)
TABLE 69 SOUTH AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 70 SOUTH AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 71 SAUDI ARABIA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 72 SAUDI ARABIA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SUBTYPE, 2019-2028 (USD MILLION)
TABLE 73 SAUDI ARABIA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 74 SAUDI ARABIA ANTIDEPRESSANTS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 75 SAUDI ARABIA SELECTIVE SEROTONIN REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 76 SAUDI ARABIA SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 77 SAUDI ARABIA TRICYCLIC ANTIDEPRESSANTS (TCAS) IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 78 SAUDI ARABIA ANTIPSYCHOTICS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 79 SAUDI ARABIA NMDA BLOCKERS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 80 SAUDI ARABIA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 81 SAUDI ARABIA ORAL IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 82 SAUDI ARABIA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY POPULATION, 2019-2028 (USD MILLION)
TABLE 83 SAUDI ARABIA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 84 SAUDI ARABIA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 85 UAE OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 86 UAE OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SUBTYPE, 2019-2028 (USD MILLION)
TABLE 87 UAE OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 88 UAE ANTIDEPRESSANTS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 89 UAE SELECTIVE SEROTONIN REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 90 UAE SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 91 UAE TRICYCLIC ANTIDEPRESSANTS (TCAS) IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 92 UAE ANTIPSYCHOTICS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 93 UAE NMDA BLOCKERS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 94 UAE OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 95 UAE ORAL IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 96 UAE OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY POPULATION, 2019-2028 (USD MILLION)
TABLE 97 UAE OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 98 UAE OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 99 KUWAIT OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 100 KUWAIT OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SUBTYPE, 2019-2028 (USD MILLION)
TABLE 101 KUWAIT OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 102 KUWAIT ANTIDEPRESSANTS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 103 KUWAIT SELECTIVE SEROTONIN REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 104 KUWAIT SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 105 KUWAIT TRICYCLIC ANTIDEPRESSANTS (TCAS) IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 106 KUWAIT ANTIPSYCHOTICS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 107 KUWAIT NMDA BLOCKERS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 108 KUWAIT OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 109 KUWAIT ORAL IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 110 KUWAIT OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY POPULATION, 2019-2028 (USD MILLION)
TABLE 111 KUWAIT OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 112 KUWAIT OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 113 ISRAEL OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 114 ISRAEL OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SUBTYPE, 2019-2028 (USD MILLION)
TABLE 115 ISRAEL OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 116 ISRAEL ANTIDEPRESSANTS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 117 ISRAEL SELECTIVE SEROTONIN REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 118 ISRAEL SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 119 ISRAEL TRICYCLIC ANTIDEPRESSANTS (TCAS) IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 120 ISRAEL ANTIPSYCHOTICS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 121 ISRAEL NMDA BLOCKERS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 122 ISRAEL OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 123 ISRAEL ORAL IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 124 ISRAEL OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY POPULATION, 2019-2028 (USD MILLION)
TABLE 125 ISRAEL OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 126 ISRAEL OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 127 EGYPT OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 128 EGYPT OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SUBTYPE, 2019-2028 (USD MILLION)
TABLE 129 EGYPT OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 130 EGYPT ANTIDEPRESSANTS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 131 EGYPT SELECTIVE SEROTONIN REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 132 EGYPT SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 133 EGYPT TRICYCLIC ANTIDEPRESSANTS (TCAS) IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 134 EGYPT ANTIPSYCHOTICS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 135 EGYPT NMDA BLOCKERS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 136 EGYPT OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 137 EGYPT ORAL IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 138 EGYPT OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY POPULATION, 2019-2028 (USD MILLION)
TABLE 139 EGYPT OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 140 EGYPT OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 141 REST OF MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
Liste des figures
LIST OF FIGURES
FIGURE 1 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET SEGMENTATION
FIGURE 2 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET DATA TRIANGULATION
FIGURE 3 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET DROC ANALYSIS
FIGURE 4 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET : MIDDLE EAST AND AFRICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET INTERVIEW DEMOGRAPHICS
FIGURE 7 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET DBMR MARKET POSITION GRID
FIGURE 8 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET MARKET APPLICATION COVERAGE GRID
FIGURE 9 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET VENDOR SHARE ANALYSIS
FIGURE 10 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET SEGMENTATION
FIGURE 11 RISE IN CLINICAL TRIALS FOR OBSESSIVE-COMPULSIVE DISORDER AND INCREASING R&D INVESTMENT BY KEY MARKET PLAYERS ARE EXPECTED TO DRIVE THE MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 12 SEVERITY SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUG MARKET IN 2021 & 2028
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES ABD CHALLENGES OF MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET
FIGURE 14 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY SEVERITY, 2020
FIGURE 15 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY SEVERITY, 2020-2028 (USD MILLION)
FIGURE 16 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY SEVERITY, CAGR (2021-2028)
FIGURE 17 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DIOSRDER (OCD) DRUG MARKET: BY SEVERITY, LIFELINE CURVE
FIGURE 18 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY SUBTYPE, 2020
FIGURE 19 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY SUBTYPE, 2020-2028 (USD MILLION)
FIGURE 20 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY SUBTYPE, CAGR (2020-2028)
FIGURE 21 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY SUBTYPE, LIFELINE CURVE
FIGURE 22 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY DRUGS, 2020
FIGURE 23 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY DRUGS, 2020-2028 (USD MILLION)
FIGURE 24 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY DRUGS, CAGR (2020-2028)
FIGURE 25 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY DRUGS, LIFELINE CURVE
FIGURE 26 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY ROUTE OF ADMINISTRATION, 2020
FIGURE 27 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY ROUTE OF ADMINISTRATION, 2020-2028 (USD MILLION)
FIGURE 28 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2020-2028)
FIGURE 29 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 30 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY POPULATION, 2020
FIGURE 31 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY POPULATION, 2020-2028 (USD MILLION)
FIGURE 32 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY POPULATION, CAGR (2021-2028)
FIGURE 33 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY, LIFELINE CURVE
FIGURE 34 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY END USER, 2020
FIGURE 35 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY END USER, 2020-2028 (USD MILLION)
FIGURE 36 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY END USER, CAGR (2021-2028)
FIGURE 37 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY END USER, LIFELINE CURVE
FIGURE 38 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY DISTRIBUTION CHANNEL, 2020
FIGURE 39 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY DISTRIBUTION CHANNEL, 2020-2028 (USD MILLION)
FIGURE 40 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)
FIGURE 41 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 42 MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: SNAPSHOT (2020)
FIGURE 43 MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY COUNTRY (2020)
FIGURE 44 MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY COUNTRY (2021 & 2028)
FIGURE 45 MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY COUNTRY (2020 & 2028)
FIGURE 46 MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY SEVERITY (2021 & 2028)
FIGURE 47 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: COMPANY SHARE 2020 (%)
Méthodologie de recherche
La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. L'étape consiste à obtenir des informations sur le marché ou des données connexes via diverses sources et stratégies. Elle comprend l'examen et la planification à l'avance de toutes les données acquises dans le passé. Elle englobe également l'examen des incohérences d'informations observées dans différentes sources d'informations. Les données de marché sont analysées et estimées à l'aide de modèles statistiques et cohérents de marché. De plus, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. Pour en savoir plus, veuillez demander un appel d'analyste ou déposer votre demande.
La méthodologie de recherche clé utilisée par l'équipe de recherche DBMR est la triangulation des données qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). Les modèles de données incluent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement des entreprises, l'analyse des brevets, l'analyse des prix, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse globale par rapport à l'analyse régionale et des parts des fournisseurs. Pour en savoir plus sur la méthodologie de recherche, envoyez une demande pour parler à nos experts du secteur.
Personnalisation disponible
Data Bridge Market Research est un leader de la recherche formative avancée. Nous sommes fiers de fournir à nos clients existants et nouveaux des données et des analyses qui correspondent à leurs objectifs. Le rapport peut être personnalisé pour inclure une analyse des tendances des prix des marques cibles, une compréhension du marché pour d'autres pays (demandez la liste des pays), des données sur les résultats des essais cliniques, une revue de la littérature, une analyse du marché des produits remis à neuf et de la base de produits. L'analyse du marché des concurrents cibles peut être analysée à partir d'une analyse basée sur la technologie jusqu'à des stratégies de portefeuille de marché. Nous pouvons ajouter autant de concurrents que vous le souhaitez, dans le format et le style de données que vous recherchez. Notre équipe d'analystes peut également vous fournir des données sous forme de fichiers Excel bruts, de tableaux croisés dynamiques (Fact book) ou peut vous aider à créer des présentations à partir des ensembles de données disponibles dans le rapport.
